ReviewCureus2026
Potential Vitamin B6 Depletion During Carbidopa/Levodopa Therapy in Parkinson's Disease: A Scoping Review of Direct Evidence.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vitamin B6 depletion during carbidopa/levodopa therapy has been linked to polyneuropathy, seizures, and anemia, but the direct evidence is heterogeneous, and causality remains uncertain. We conducted a focused scoping review of direct empirical evidence on vitamin B6 biology during carbidopa/levodopa exposure and on vitamin B6-related clinical consequences supported by biochemical assessment. We also included studies of biomarker-guided monitoring, supplementation, and direct carbidopa-vitamin B6 chemistry. PubMed, Scopus, and Web of Science were searched without date or language limits on July 21, 2026. Of 656 database records, 448 unique records were screened, 161 reports were assessed in full, and 36 reports met the focused criteria. These comprised 34 reports involving human participants, including 18 group-level studies and 16 case reports or series, and two nonclinical experimental reports. Direct chemistry supports stable carbidopa-pyridoxal 5'-phosphate binding, and high-dose carbidopa exposure in dogs produced a preventable deficiency phenotype. Human studies reported lower vitamin B6 biomarkers most consistently with high or rapidly increased exposure, but findings were not uniform, and dose, route, advanced disease, nutrition, supplementation, and overlapping cohorts could not be separated. Severe deficiency accompanied axonal neuropathy, refractory seizures, and microcytic or sideroblastic-pattern anemia in individual case reports. No study established population-level incidence of vitamin B6 depletion or attributable clinical outcomes, a causal exposure threshold, an optimal testing interval, or a prophylactic dose. Direct vitamin B6 testing, interpreted with laboratory-specific reference intervals and complementary nutritional, hematologic, and neurologic assessment, is better supported by the available evidence than reliance on homocysteine alone. Prospective exposure-resolved studies are required before route-specific risk or universal supplementation can be recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.